 TEL AVIV, Israel, Oct. 29, 2020 PRNewswire -- BioLineRx Ltd. NASDAQ: BLRX TASE: BLRX, a clinical-stage biopharmaceutical Company focused on oncology, today announced that the Companys lead drug candidate, the CXCR4-inhibitor Motixafortide, will be tested in combination with the... 